This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wiggin, T. D. Articles by Feldman, E. L. Search for Related Content PubMed PubMed Citation Articles by Wiggin, T. D. Articles by Feldman, E. L. Pubmed/NCBI databases GEO DataSet Compound via MeSH Substance via MeSH Medline Plus Health Information Diabetic Nerve Problems

Rosiglitazone Treatment Reduces Diabetic Neuropathy in Streptozotocin-Treated DBA/2J Mice

Department of Neurology (T.D.W., K.A.S., E.L.F.), and Department of Internal Medicine (M.K., S.P., F.C.B.), University of Michigan, Ann Arbor, Michigan 48109

Address all correspondence and requests for reprints to: Eva L. Feldman, M.D., Ph.D., University of Michigan, Department of Neurology, 5017 Basic Science Research Building, 109 Zina Pitcher Road, Ann Arbor, Michigan 48109-2200. E-mail: efeldman{at}umich.edu.

Diabetic neuropathy (DN) is a common complication of diabetes. Currently, there is no drug treatment to prevent or slow the development of DN. Rosiglitazone (Rosi) is a potent insulin sensitizer and may also slow the development of DN by a mechanism independent of its effect on hyperglycemia. A two by two design was used to test the effect of Rosi treatment on the development of DN. Streptozotocin-induced diabetic DBA/2J mice were treated with Rosi. DN and oxidative stress were quantified, and gene expression was profiled using the Affymetrix Mouse Genome 430 2.0 microarray platform. An informatics approach identified key regulatory elements activated by Rosi. Diabetic DBA/2J mice developed severe hyperglycemia, DN, and elevated oxidative stress. Rosi treatment did not affect hyperglycemia but did reduce oxidative stress and prevented the development of thermal hypoalgesia. Two novel transcription factor binding modules were identified that may control genes correlated to changes in DN after Rosi treatment: SP1F_ZBPF and EGRF_EGRF. These targets may be useful in designing drugs with the same efficacy as Rosi in treating DN but with fewer undesirable effects.

This article has been cited by other articles:

				A. M. Vincent, J. M. Hayes, L. L. McLean, A. Vivekanandan-Giri, S. Pennathur, and E. L. Feldman Dyslipidemia-Induced Neuropathy in Mice: The Role of oxLDL/LOX-1 Diabetes, October 1, 2009; 58(10): 2376 - 2385. [Abstract] [Full Text] [PDF]